[1] Patnaik MM, Kamath PS, Simonetto DA, et al. Hepatic manifestations of telomere biology disorders. J Hepatol, 2018, 69:736-743.
[2] Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telomeropathies. Blood, 2014, 124: 2775-2783.
[3] Hartmann D, Srivastava U, Thaler M, et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology, 2011, 53:1608-1617.
[4] Calado RT, Brudno J, Mehta P, et al. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology, 2011, 53:1600-1607.
[5] Cuervo H, Nielsen CM, Simonetto DA, et al. Endothelial notch signaling is essential to prevent hepatic vascular malformations in mice. Hepatology, 2016, 64:1302-1316.
[6] Rothweiler S, Terracciano L, Tornillo L, et al. Downregulation of the endothelial genes Notch1 and ephrinB2 in patients with nodular regenerative hyperplasia. Liver Int, 2014, 34:594-603.
[7] Gorgy AI, Jonassaint NL, Stanley SE, et al. Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders. Chest, 2015, 148:1019-1026.
[8] Jharap B, van Asseldonk DP, de Boer NK, et al. Diagnosing nodular regenerative hyperplasia of the liver is thwarted by low interobserver agreement. PLoS One, 2015, 10: e0120299.
[9] Siramolpiwat S, Seijo S, Miquel R, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatology, 2014, 59: 2276-2285.
[10] Indaram M, Agarwal S, Yonekawa Y. Exudative vitreoretinopathy in dyskeratosis congenita. Ophthalmology, 2017, 124:1246.
[11] Mahansaria SS, Kumar S, Bharathy KG, et al. Liver transplantation after bone marrow transplantation for end stage liver disease with severe hepatopulmonary syndrome in dyskeratosis congenita: a literature first. J Clin Exp Hepatol, 2015, 5: 344-347.
[12] Khincha PP, Wentzensen IM, Giri N, et al. Response to androgen therapy in patients with dyskeratosis congenita. Br J Haematol, 2014, 165:349-357.
[13] Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane review. Am J Gastroenterol, 2002, 97:1674-1681.
[14] Sinclair M, Grossmann M, Hoermann R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial. J Hepatol, 2016, 65:906-913. 14. |
